Alec C. Kimmelman: Difference between revisions

By /

From Wikipedia, the free encyclopedia

Content deleted Content added


 
Line 15: Line 15:

=== Research ===

=== Research ===

Dr. Kimmelman is a [[National Institutes of Health]]–funded investigator whose work has primarily focused on pancreatic cancer and the key biological functions of Ras oncogenes.<ref>{{Cite web |last=Staff |first=Brooklyn Eagle |date=2025-04-02 |title=NYU Langone Health appoints cancer specialist as medical school’s new CEO and dean |url=https://brooklyneagle.com/articles/2025/04/02/nyu-langone-health-appoints-new-ceo-and-dean/ |access-date=2025-10-13 |website=Brooklyn Eagle |language=en-US}}</ref><ref name=”:1″ /> Kimmelman’s laboratory was focused on the basic and translational science of pancreatic cancer.<ref name=”:3″>{{Cite web |date=2013-04-01 |title=Pancreatic Cancer Loophole {{!}} Harvard Medical School |url=https://hms.harvard.edu/news/pancreatic-cancer-loophole |access-date=2025-10-13 |website=hms.harvard.edu |language=en}}</ref> His research identified unique metabolic pathways and revealed how the Kras oncogene reprograms tumor metabolism.<ref name=”:3″ />

Dr. Kimmelman is a [[National Institutes of Health]]–funded investigator whose work has primarily focused on pancreatic cancer and the key biological functions of Ras oncogenes.<ref>{{Cite web |last=Staff |first=Brooklyn Eagle |date=2025-04-02 |title=NYU Langone Health appoints cancer specialist as medical school’s new CEO and dean |url=https://brooklyneagle.com/articles/2025/04/02/nyu-langone-health-appoints-new-ceo-and-dean/ |access-date=2025-10-13 |website=Brooklyn Eagle |language=en-US}}</ref><ref name=”:1″ /> Kimmelman’s laboratory was focused on the basic and translational science of pancreatic cancer.<ref name=”:3″>{{Cite web |date=2013-04-01 |title=Pancreatic Cancer Loophole {{!}} Harvard Medical School |url=https://hms.harvard.edu/news/pancreatic-cancer-loophole |access-date=2025-10-13 |website=hms.harvard.edu |language=en}}</ref> His research identified unique metabolic pathways and revealed how the Kras oncogene reprograms tumor metabolism.<ref name=”:3″ />

Dr. Kimmelman’s research has been published in journals including ”Cell, Science”, and ”Genes & Development.”<ref>{{Cite journal |last=Kimmelman |first=Alec C. |date=2011-10-01 |title=The dynamic nature of autophagy in cancer |url=http://genesdev.cshlp.org/content/25/19/1999 |journal=Genes & Development |language=en |volume=25 |issue=19 |pages=1999–2010 |doi=10.1101/gad.17558811 |issn=0890-9369 |pmid=21979913}}</ref><ref>{{Cite journal |last=Mukhopadhyay |first=Subhadip |last2=Encarnación-Rosado |first2=Joel |last3=Lin |first3=Elaine Y. |last4=Sohn |first4= |last5=Zhang |first5=Huan |last6=Mancias |first6=Joseph D. |last7=Kimmelman |first7=Alec C. |date=2023-04-19 |title=Autophagy supports mitochondrial metabolism through the regulation of iron homeostasis in pancreatic cancer |url=https://www.science.org/doi/10.1126/sciadv.adf9284 |journal=Science Advances |volume=9 |issue=16 |pages=eadf9284 |doi=10.1126/sciadv.adf9284 |pmc=10115412 |pmid=37075122}}</ref><ref>{{Cite journal |last=Biancur |first=Douglas E. |last2=Kapner |first2=Kevin S. |last3=Yamamoto |first3=Keisuke |last4=Banh |first4=Robert S. |last5=Neggers |first5=Jasper E. |last6=Sohn |first6=Albert S. W. |last7=Wu |first7=Warren |last8=Manguso |first8=Robert T. |last9=Brown |first9=Adam |last10=Root |first10=David E. |last11=Aguirre |first11=Andrew J. |last12=Kimmelman |first12=Alec C. |date=2021-01-05 |title=Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer |url=https://www.cell.com/cell-metabolism/abstract/S1550-4131(20)30551-9 |journal=Cell Metabolism |language=English |volume=33 |issue=1 |pages=199–210.e8 |doi=10.1016/j.cmet.2020.10.018 |issn=1550-4131 |pmid=33152323}}</ref>

==References==

==References==

Latest revision as of 16:13, 13 October 2025

Alec C. Kimmelman, MD, PhD, is an American physician and researcher. Kimmelman is dean of NYU Grossman School of Medicine and chief executive officer of NYU Langone Health.[1]

Early life and education

[edit]

Dr. Kimmelman earned his bachelor’s degree from Cornell University and completed a dual MD/PhD through the Medical Scientist Training Program at the Icahn School of Medicine at Mount Sinai.[2] He went on to join Harvard Medical School as a clinical fellow, completing his residency in radiation oncology and a postdoctoral fellowship at Dana-Farber.[3][2]

Academic appointments

[edit]

Prior to joining NYU Langone, Kimmelman ran a research program at Dana-Farber Cancer Institute focused on pancreatic cancer.[2] He was also an attending physician at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, where he specialized in gastrointestinal malignancies, including pancreatic cancer.[4][5]

Dr. Kimmelman joined NYU Langone in 2016 and has held several leadership roles at the medical center.[6] He served as director of NYU Langone’s Laura and Isaac Perlmutter Cancer Center, the Laura and Isaac Perlmutter Professor of Radiation Oncology, the Anita Steckler and Joseph Steckler Chair of the Department of Radiation Oncology, and chair of the Department of Radiation Oncology at NYU Grossman School of Medicine.[7][6] He was also associate dean of cancer research at the school, served on the Executive Management Committee of the Perlmutter Cancer Center, and co-led its Cancer Cell Biology Program.[6]

In 2025, Dr. Kimmelman was appointed dean of NYU Grossman School of Medicine and chief executive officer of NYU Langone Health.[1]

Dr. Kimmelman is a National Institutes of Health–funded investigator whose work has primarily focused on pancreatic cancer and the key biological functions of Ras oncogenes.[8][2] Kimmelman’s laboratory was focused on the basic and translational science of pancreatic cancer.[9] His research identified unique metabolic pathways and revealed how the Kras oncogene reprograms tumor metabolism.[9]

Dr. Kimmelman’s research has been published in journals including Cell, Science, and Genes & Development.[10][11][12]

  1. ^ a b Gioia, Amelia Hernandez; Kantheti, Lekhya (2025-04-02). “NYU Langone names new dean and CEO”. Washington Square News. Retrieved 2025-10-13.
  2. ^ a b c d “NYU Langone Appoints Alec Kimmelman, MD, PhD, as Chair of Radiation Oncology”. ascopost.com. Retrieved 2025-10-13.
  3. ^ Gioia, Amelia Hernandez; Kantheti, Lekhya (2025-04-02). “NYU Langone names new dean and CEO”. Washington Square News. Retrieved 2025-10-13.
  4. ^ “Alec Kimmelman, MD, PhD”. Pancreatic Cancer Action Network. Retrieved 2025-10-13.
  5. ^ “Alec C. Kimmelman Appointed As Next CEO Of Leading Medical Institution | The Lifesciences Magazine”. 2025-04-01. Retrieved 2025-10-13.
  6. ^ a b c “Alec Kimmelman named director of Perlmutter Cancer Center, quickly replacing ousted Benjamin Neel”. The Cancer Letter. 2023-12-01. Retrieved 2025-10-13.
  7. ^ Communications, NYU Web. “More than Two Dozen NYU Researchers Among the World’s Most Cited”. www.nyu.edu. Retrieved 2025-10-13.
  8. ^ Staff, Brooklyn Eagle (2025-04-02). “NYU Langone Health appoints cancer specialist as medical school’s new CEO and dean”. Brooklyn Eagle. Retrieved 2025-10-13.
  9. ^ a b “Pancreatic Cancer Loophole | Harvard Medical School”. hms.harvard.edu. 2013-04-01. Retrieved 2025-10-13.
  10. ^ Kimmelman, Alec C. (2011-10-01). “The dynamic nature of autophagy in cancer”. Genes & Development. 25 (19): 1999–2010. doi:10.1101/gad.17558811. ISSN 0890-9369. PMID 21979913.
  11. ^ Mukhopadhyay, Subhadip; Encarnación-Rosado, Joel; Lin, Elaine Y.; Sohn; Zhang, Huan; Mancias, Joseph D.; Kimmelman, Alec C. (2023-04-19). “Autophagy supports mitochondrial metabolism through the regulation of iron homeostasis in pancreatic cancer”. Science Advances. 9 (16): eadf9284. doi:10.1126/sciadv.adf9284. PMC 10115412. PMID 37075122.{{cite journal}}: CS1 maint: article number as page number (link)
  12. ^ Biancur, Douglas E.; Kapner, Kevin S.; Yamamoto, Keisuke; Banh, Robert S.; Neggers, Jasper E.; Sohn, Albert S. W.; Wu, Warren; Manguso, Robert T.; Brown, Adam; Root, David E.; Aguirre, Andrew J.; Kimmelman, Alec C. (2021-01-05). “Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer”. Cell Metabolism. 33 (1): 199–210.e8. doi:10.1016/j.cmet.2020.10.018. ISSN 1550-4131. PMID 33152323.

Must Read

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top